Latest Financial Health News

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

Spectur Limited reports a positive operating cash flow for Q4 FY25, driven by revenue growth and cost-cutting, alongside strategic investments in cloud and connectivity technology.

Rand Mining Ltd reported solid gold production of 8,916 ounces in the June 2025 quarter, alongside improved cash flow and ongoing exploration success at key Western Australian projects.

Centuria Capital No. 2 Fund confirms full compliance with note terms and stable loan positions in its Q4 FY25 report, reassuring investors amid a steady operational quarter.

Biotron Limited has successfully raised $1.27 million through an entitlement issue to fund its antiviral drug development, including a promising Hepatitis B compound that cleared its initial animal safety study.

N1 Holdings reports a profitable FY2025 with strategic expansion into Australia's largest aggregator panel and launches AI-driven credit tools to enhance SME lending operations.

Minbos Resources has secured key financing and made significant construction strides on its Angolan phosphate fertilizer plant, while rolling out promising new fertilizer blends to support local agriculture.

Radiopharm Theranostics reports significant progress in its oncology radiopharmaceutical pipeline, including FDA Fast Track designation and dose escalation approvals, supported by a solid cash runway through mid-2026.

Careteq Limited reports a significant reduction in operating cash outflow and modest revenue growth for FY25, while facing delays in its key platform integration and a dispute with the ATO over R&D claims.

Clime Investment Management has reported a solid operating profit for the June quarter, declared a fully franked dividend, and announced strategic expansions in staff and product offerings.

OpenLearning Limited reported a robust Q2 FY25 with 22% year-on-year SaaS ARR growth to $2.65 million, driven by significant multi-year contract wins and expanding global customer base. The company’s AI-powered LMS strategy is delivering larger deals and improved cash flow metrics.

SomnoMed reports a robust Q4 FY25 with 25% revenue growth and a milestone of treating over 1 million patients, while gearing up for significant capacity expansion and clinical advancements.